What is Integra Lifesciences Hldgs Cp's earnings per share (EPS)?

Integra Lifesciences Hldgs Cp (IART) reported diluted earnings per share of $-6.74 for fiscal year 2025. This represents a -7388.9% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Integra Lifesciences Hldgs Cp Financials

IART

Source SEC Filings (10-K/10-Q) Data as of Mar 31, 2026 Currency USD FYE December

This page shows Integra Lifesciences Hldgs Cp (IART) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 18 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI IART FY2025 2026-05-05

Nearly flat sales masked shrinking unit economics and a balance-sheet reset that pushed reported earnings deep into loss.

The gap between the -$516.8M net loss and $50.4M operating cash flow shows reported earnings and operating cash reality diverged unusually sharply in FY2025. With goodwill also dropping by $481.8M from FY2024, the damage looks more like a balance-sheet reset than a same-sized collapse in cash coming in from customers.

Across FY2023-FY2025, revenue barely moved, but gross margin fell from 57.4% to 50.9%. Inventory build from $389.6M to $492.7M suggests more cash became tied up in product even as each sale carried less gross profit, which makes the operating model less forgiving.

Short-term liquidity improved after FY2024: the current ratio recovered from 1.2x to 2.5x as current liabilities fell, easing near-term balance-sheet pressure. But free cash flow still slid from $73.1M in FY2023 to -$31.1M in FY2025, so the balance sheet is absorbing more strain than the income statement alone reveals.

Financial Health Signals

Financial Health Score 38/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Integra Lifesciences Hldgs Cp's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability

Integra Lifesciences Hldgs Cp has an operating margin of -30.2%, meaning the company retains $-30 of operating profit per $100 of revenue. This below-average margin results in a low score of 15/100, suggesting thin profitability after operating expenses. This is down from 1.8% the prior year.

Growth

Integra Lifesciences Hldgs Cp's revenue grew a modest 1.5% year-over-year to $1.6B. This slow but positive growth earns a score of 42/100.

Leverage

Integra Lifesciences Hldgs Cp has a moderate D/E ratio of 0.70. This balance of debt and equity financing earns a leverage score of 54/100.

Liquidity

With a current ratio of 2.54, Integra Lifesciences Hldgs Cp holds $2.54 in current assets for every $1 of short-term obligations. This comfortable liquidity earns a score of 70/100.

Cash Flow

While Integra Lifesciences Hldgs Cp generated $50.4M in operating cash flow, capex of $81.4M consumed most of it, leaving -$31.1M in free cash flow. This results in a low score of 30/100, reflecting heavy capital investment rather than weak cash generation.

Returns

Integra Lifesciences Hldgs Cp generates a -49.5% ROE, indicating limited profit relative to shareholders' investment. This results in a returns score of 17/100. This is down from -0.4% the prior year.

Altman Z-Score Distress

0.74

Integra Lifesciences Hldgs Cp scores 0.74, below the 1.81 distress threshold. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

4/8

Integra Lifesciences Hldgs Cp passes 4 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 2 of 4 profitability signals pass, 1 of 2 leverage/liquidity signals pass, 1 of 2 efficiency signals pass.

Earnings Quality Mixed

-0.10x

For every $1 of reported earnings, Integra Lifesciences Hldgs Cp generates $-0.10 in operating cash flow ($50.4M OCF vs -$516.8M net income). This mixed ratio suggests some earnings may rely on non-cash accounting items.

Interest Coverage At Risk

-5.7x

Integra Lifesciences Hldgs Cp earns $-5.7 in operating income for every $1 of interest expense (-$493.4M vs $86.3M). This narrow margin raises concern about the company's ability to service its debt if operating income declines.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$1.6B

YoY+1.5%

5Y CAGR+3.6%

10Y CAGR+6.4%

Integra Lifesciences Hldgs Cp generated $1.6B in revenue in fiscal year 2025. This represents an increase of 1.5% from the prior year.

EBITDA

-$433.6M

YoY-570.8%

Integra Lifesciences Hldgs Cp's EBITDA was -$433.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization. This represents a decrease of 570.8% from the prior year.

Net Income

-$516.8M

YoY-7389.9%

Integra Lifesciences Hldgs Cp reported -$516.8M in net income in fiscal year 2025. This represents a decrease of 7389.9% from the prior year.

EPS (Diluted)

$-6.74

YoY-7388.9%

Integra Lifesciences Hldgs Cp earned $-6.74 per diluted share (EPS) in fiscal year 2025. This represents a decrease of 7388.9% from the prior year.

Cash & Balance Sheet

Free Cash Flow

-$31.1M

YoY-224.4%

Integra Lifesciences Hldgs Cp generated -$31.1M in free cash flow in fiscal year 2025, representing cash available after capex. This represents a decrease of 224.4% from the prior year.

Cash & Debt

$235.0M

YoY-4.6%

5Y CAGR-12.9%

10Y CAGR+17.2%

Integra Lifesciences Hldgs Cp held $235.0M in cash against $726.6M in long-term debt as of fiscal year 2025.

Dividends Per Share

N/A

Shares Outstanding

N/A

Margins & Returns

Gross Margin

50.9%

YoY-3.9pp

5Y CAGR-11.2pp

10Y CAGR-12.1pp

Integra Lifesciences Hldgs Cp's gross margin was 50.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs. This is down 3.9 percentage points from the prior year.

Operating Margin

-30.2%

YoY-31.9pp

5Y CAGR-41.2pp

10Y CAGR-39.2pp

Integra Lifesciences Hldgs Cp's operating margin was -30.2% in fiscal year 2025, reflecting core business profitability. This is down 31.9 percentage points from the prior year.

Net Margin

-31.6%

YoY-31.2pp

5Y CAGR-41.4pp

10Y CAGR-31.2pp

Integra Lifesciences Hldgs Cp's net profit margin was -31.6% in fiscal year 2025, showing the share of revenue converted to profit. This is down 31.2 percentage points from the prior year.

Return on Equity

-49.5%

YoY-49.1pp

5Y CAGR-58.4pp

10Y CAGR-49.1pp

Integra Lifesciences Hldgs Cp's ROE was -49.5% in fiscal year 2025, measuring profit generated per dollar of shareholder equity. This is down 49.1 percentage points from the prior year.

Capital Allocation

R&D Spending

$99.0M

YoY-14.2%

5Y CAGR+5.0%

10Y CAGR+6.9%

Integra Lifesciences Hldgs Cp invested $99.0M in research and development in fiscal year 2025. This represents a decrease of 14.2% from the prior year.

Share Buybacks

$221K

YoY-99.6%

5Y CAGR-70.6%

Integra Lifesciences Hldgs Cp spent $221K on share buybacks in fiscal year 2025, returning capital to shareholders by reducing shares outstanding. This represents a decrease of 99.6% from the prior year.

Capital Expenditures

$81.4M

YoY-22.0%

5Y CAGR+15.9%

10Y CAGR+9.3%

Integra Lifesciences Hldgs Cp invested $81.4M in capex in fiscal year 2025, funding long-term assets and infrastructure. This represents a decrease of 22.0% from the prior year.

IART Income Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Revenue	$1.6B+1.5%	$1.6B+4.5%	$1.5B-1.0%	$1.6B+1.0%	$1.5B+12.4%	$1.4B
Cost of Revenue	$803.6M+10.3%	$728.5M+10.9%	$656.8M+11.8%	$587.4M-1.7%	$597.8M+14.8%	$520.8M
Gross Profit	$831.6M-5.7%	$882.1M-0.3%	$884.7M-8.8%	$970.3M+2.7%	$944.6M+11.0%	$851.0M
R&D Expenses	$99.0M-14.2%	$115.4M+10.7%	$104.2M+3.0%	$101.2M+8.8%	$93.1M+20.3%	$77.4M
SG&A Expenses	$699.7M-2.4%	$717.0M+9.2%	$656.6M+6.5%	$616.3M-3.3%	$637.4M+7.2%	$594.5M
Operating Income	-$493.4M-1836.5%	$28.4M-74.5%	$111.5M-53.3%	$238.9M+21.1%	$197.2M+30.3%	$151.4M
Interest Expense	$86.3M+22.1%	$70.6M+37.5%	$51.4M+3.6%	$49.6M-1.6%	$50.4M-29.6%	$71.6M
Income Tax	-$47.0M-316.4%	-$11.3M-184.7%	$13.3M-60.0%	$33.3M-26.9%	$45.6M+213.0%	-$40.4M
Net Income	-$516.8M-7389.9%	-$6.9M-110.2%	$67.7M-62.5%	$180.6M+6.8%	$169.1M+26.3%	$133.9M
EPS (Diluted)	$-6.74-7388.9%	$-0.09-110.7%	$0.84-61.1%	$2.16+9.1%	$1.98+26.1%	$1.57

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Revenue	$391.9M-9.9%	$434.9M+8.2%	$402.1M-3.3%	$415.6M+8.6%	$382.7M-13.6%	$442.6M+16.2%	$380.8M-8.9%	$418.2M
Cost of Revenue	$174.9M-18.3%	$214.1M+9.7%	$195.1M-5.4%	$206.3M+9.6%	$188.2M-2.8%	$193.6M+7.2%	$180.6M-6.1%	$192.3M
Gross Profit	$217.0M-1.8%	$220.9M+6.7%	$207.0M-1.1%	$209.3M+7.7%	$194.4M-21.9%	$249.1M+24.4%	$200.2M-11.4%	$225.9M
R&D Expenses	$23.5M-5.2%	$24.8M+10.4%	$22.5M-16.8%	$27.0M+9.2%	$24.7M-20.8%	$31.2M+13.8%	$27.4M-7.8%	$29.8M
SG&A Expenses	$178.2M+5.3%	$169.3M+0.1%	$169.0M-6.0%	$179.9M-0.9%	$181.5M+1.7%	$178.5M+0.7%	$177.2M-9.4%	$195.5M
Operating Income	$11.5M-50.2%	$23.0M+95.9%	$11.8M+102.3%	-$512.7M-3208.2%	-$15.5M-143.5%	$35.6M+537.1%	-$8.2M-169.1%	-$3.0M
Interest Expense	$22.5M-5.1%	$23.7M+4.2%	$22.7M+8.0%	$21.0M+11.8%	$18.8M-0.9%	$19.0M-2.0%	$19.4M+3.9%	$18.7M
Income Tax	$2.2M-63.3%	$6.0M+523.5%	-$1.4M+97.0%	-$46.9M-888.4%	-$4.7M-252.7%	$3.1M+132.1%	-$9.7M-247.4%	-$2.8M
Net Income	-$4.6M-127.4%	-$2.0M+62.4%	-$5.4M+98.9%	-$484.1M-1813.9%	-$25.3M-229.9%	$19.5M+282.1%	-$10.7M+13.8%	-$12.4M
EPS (Diluted)	$-0.06	N/A	$-0.07+98.9%	$-6.31-1812.1%	$-0.33	N/A	$-0.14+12.5%	$-0.16

IART Balance Sheet

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Total Assets	$3.6B-10.8%	$4.0B+6.8%	$3.8B-2.8%	$3.9B+2.8%	$3.8B+4.6%	$3.6B
Current Assets	$1.2B+7.2%	$1.1B+2.2%	$1.1B-8.9%	$1.2B+0.7%	$1.2B-6.7%	$1.2B
Cash & Equivalents	$235.0M-4.6%	$246.4M-10.9%	$276.4M-39.5%	$456.7M-11.1%	$513.4M+9.2%	$470.2M
Inventory	$492.7M+14.8%	$429.1M+10.1%	$389.6M+20.0%	$324.6M+2.3%	$317.4M+2.3%	$310.1M
Accounts Receivable	$278.8M+2.4%	$272.4M+5.0%	$259.3M-1.6%	$263.5M+13.6%	$231.8M+2.8%	$225.5M
Goodwill	$615.2M-43.9%	$1.1B+3.9%	$1.1B+1.6%	$1.0B+2.5%	$1.0B+8.7%	$932.4M
Total Liabilities	$2.6B+2.7%	$2.5B+13.6%	$2.2B+5.2%	$2.1B-0.6%	$2.1B-0.1%	$2.1B
Current Liabilities	$456.0M-50.6%	$922.1M+200.4%	$307.0M-4.3%	$320.9M-5.6%	$340.0M-15.2%	$401.0M
Long-Term Debt	$726.6M-4.5%	$760.5M-1.9%	$775.0M0.0%	$775.0M-8.1%	$843.8M-3.8%	$877.5M
Total Equity	$1.0B-32.5%	$1.5B-2.7%	$1.6B-12.0%	$1.8B+7.1%	$1.7B+11.2%	$1.5B
Retained Earnings	$423.4M-54.9%	$939.9M-0.7%	$946.9M+7.7%	$879.1M+25.8%	$698.6M+31.2%	$532.3M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Total Assets	$3.6B-0.7%	$3.6B-1.2%	$3.6B-0.6%	$3.7B-9.5%	$4.1B+0.4%	$4.0B-0.7%	$4.1B-0.2%	$4.1B
Current Assets	$1.2B+1.1%	$1.2B+1.4%	$1.1B+0.1%	$1.1B+3.2%	$1.1B+2.4%	$1.1B-1.6%	$1.1B-1.1%	$1.1B
Cash & Equivalents	$236.8M+0.7%	$235.0M+1.2%	$232.2M+6.5%	$217.9M-8.9%	$239.1M-3.0%	$246.4M+14.5%	$215.2M0.0%	$215.2M
Inventory	$495.0M+0.5%	$492.7M+0.7%	$489.1M+5.2%	$465.1M+4.4%	$445.4M+3.8%	$429.1M-1.8%	$436.9M+3.6%	$421.8M
Accounts Receivable	$264.4M-5.2%	$278.8M+6.4%	$262.2M-7.9%	$284.5M+12.7%	$252.4M-7.3%	$272.4M+9.7%	$248.3M-8.4%	$271.2M
Goodwill	$613.2M-0.3%	$615.2M0.0%	$615.2M-0.2%	$616.4M-44.2%	$1.1B+0.8%	$1.1B-1.8%	$1.1B+1.1%	$1.1B
Total Liabilities	$2.5B-0.9%	$2.6B-1.9%	$2.6B-0.8%	$2.6B+4.0%	$2.5B+1.5%	$2.5B-2.0%	$2.5B+0.2%	$2.5B
Current Liabilities	$346.8M-23.9%	$456.0M+25.3%	$364.1M-60.8%	$929.8M+1.2%	$918.5M-0.4%	$922.1M+1.0%	$912.6M+178.0%	$328.3M
Long-Term Debt	$716.9M-1.3%	$726.6M-1.3%	$736.3M-1.3%	$745.9M-1.3%	$755.6M-0.6%	$760.5M-0.6%	$765.3M-0.6%	$770.2M
Total Equity	$1.0B-0.1%	$1.0B+0.6%	$1.0B-0.1%	$1.0B-31.9%	$1.5B-1.4%	$1.5B+1.6%	$1.5B-0.8%	$1.5B
Retained Earnings	$418.8M-1.1%	$423.4M-0.4%	$425.1M-1.3%	$430.5M-52.9%	$914.6M-2.7%	$939.9M+2.1%	$920.5M-1.1%	$931.2M

IART Cash Flow Statement

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Operating Cash Flow	$50.4M-61.1%	$129.4M-7.6%	$140.0M-47.1%	$264.5M-15.4%	$312.4M+53.3%	$203.8M
Capital Expenditures	$81.4M-22.0%	$104.4M+56.2%	$66.9M+57.9%	$42.3M-11.8%	$48.0M+23.5%	$38.9M
Free Cash Flow	-$31.1M-224.4%	$25.0M-65.8%	$73.1M-67.1%	$222.1M-16.0%	$264.4M+60.3%	$164.9M
Investing Cash Flow	-$108.1M+72.3%	-$390.8M-315.0%	-$94.2M-60.8%	-$58.6M+63.7%	-$161.4M-137.2%	-$68.1M
Financing Cash Flow	$28.3M-88.1%	$237.9M+203.5%	-$229.9M+8.7%	-$252.0M-156.5%	-$98.2M-180.8%	$121.6M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	$221K-99.6%	$52.5M-80.9%	$275.0M+120.0%	$125.0M	$0-100.0%	$100.0M

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Operating Cash Flow	$9.8M-17.0%	$11.8M-71.1%	$40.9M+358.6%	$8.9M+179.2%	-$11.3M-122.2%	$50.7M+125.7%	$22.5M-44.3%	$40.4M
Capital Expenditures	$14.8M-13.7%	$17.2M+13.6%	$15.2M-24.8%	$20.1M-30.3%	$28.9M-2.3%	$29.6M-0.2%	$29.6M-0.2%	$29.7M
Free Cash Flow	-$5.0M+6.5%	-$5.4M-121.0%	$25.8M+329.4%	-$11.2M+72.1%	-$40.2M-290.1%	$21.1M+395.2%	-$7.2M-167.0%	$10.7M
Investing Cash Flow	-$14.8M+57.5%	-$34.9M-123.9%	-$15.6M+28.0%	-$21.6M+39.7%	-$35.9M-745.4%	-$4.2M+59.1%	-$10.4M+96.8%	-$322.2M
Financing Cash Flow	$8.3M-65.9%	$24.3M+337.6%	-$10.2M+51.5%	-$21.1M-159.8%	$35.4M+594.8%	-$7.2M+64.1%	-$19.9M+78.8%	-$93.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	$0	$0	N/A	N/A	$2.5M	$0-100.0%	$50.0M

IART Financial Ratios

Metric	FY25	FY24	FY23	FY22	FY21	FY20
Gross Margin	50.9%-3.9pp	54.8%-2.6pp	57.4%-4.9pp	62.3%+1.0pp	61.2%-0.8pp	62.0%
Operating Margin	-30.2%-31.9pp	1.8%-5.5pp	7.2%-8.1pp	15.3%+2.5pp	12.8%+1.8pp	11.0%
Net Margin	-31.6%-31.2pp	-0.4%-4.8pp	4.4%-7.2pp	11.6%+0.6pp	11.0%+1.2pp	9.8%
Return on Equity	-49.5%-49.1pp	-0.4%-4.7pp	4.3%-5.8pp	10.0%-0.0pp	10.0%+1.2pp	8.8%
Return on Assets	-14.3%-14.2pp	-0.2%-2.0pp	1.8%-2.8pp	4.6%+0.2pp	4.5%+0.8pp	3.7%
Current Ratio	2.54+1.4	1.17-2.3	3.45-0.2	3.62+0.2	3.39+0.3	3.09
Debt-to-Equity	0.70+0.2	0.490.0	0.49+0.1	0.43-0.1	0.50-0.1	0.58
FCF Margin	-1.9%-3.5pp	1.6%-3.2pp	4.7%-9.5pp	14.3%-2.9pp	17.1%+5.1pp	12.0%

Metric	Q1'26	Q4'25	Q3'25	Q2'25	Q1'25	Q4'24	Q3'24	Q2'24
Gross Margin	55.4%+4.6pp	50.8%-0.7pp	51.5%+1.1pp	50.4%-0.4pp	50.8%-5.5pp	56.3%+3.7pp	52.6%-1.4pp	54.0%
Operating Margin	2.9%-2.4pp	5.3%+2.4pp	2.9%+126.3pp	-123.4%-119.3pp	-4.0%-12.1pp	8.1%+10.2pp	-2.1%-1.4pp	-0.7%
Net Margin	-1.2%-0.7pp	-0.5%+0.9pp	-1.3%+115.1pp	-116.5%-109.9pp	-6.6%-11.0pp	4.4%+7.2pp	-2.8%+0.2pp	-3.0%
Return on Equity	-0.4%-0.2pp	-0.2%+0.3pp	-0.5%+46.1pp	-46.6%-45.0pp	-1.7%-2.9pp	1.3%+2.0pp	-0.7%+0.1pp	-0.8%
Return on Assets	-0.1%-0.1pp	-0.1%+0.1pp	-0.1%+13.1pp	-13.2%-12.6pp	-0.6%-1.1pp	0.5%+0.7pp	-0.3%+0.0pp	-0.3%
Current Ratio	3.38+0.8	2.54-0.6	3.14+1.9	1.23+0.0	1.21+0.0	1.17-0.0	1.20-2.2	3.39
Debt-to-Equity	0.690.0	0.70-0.0	0.710.0	0.72+0.2	0.500.0	0.49-0.0	0.500.0	0.50
FCF Margin	-1.3%-0.1pp	-1.2%-7.6pp	6.4%+9.1pp	-2.7%+7.8pp	-10.5%-15.3pp	4.8%+6.7pp	-1.9%-4.4pp	2.6%

Similar Companies

SS Innovations SSII

$756.5M

Adapthealth Corp AHCO

$1.4B

Establishment Labs Hldgs Inc ESTA

$2.6B

Inmode Ltd. INMD

$862.8M

Beta Bionics, Inc. BBNX

$732.1M

Frequently Asked Questions

What is Integra Lifesciences Hldgs Cp's annual revenue?

Integra Lifesciences Hldgs Cp (IART) reported $1.6B in total revenue for fiscal year 2025. This represents a 1.5% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Integra Lifesciences Hldgs Cp's revenue growing?

Integra Lifesciences Hldgs Cp (IART) revenue grew by 1.5% year-over-year, from $1.6B to $1.6B in fiscal year 2025.

Is Integra Lifesciences Hldgs Cp profitable?

No, Integra Lifesciences Hldgs Cp (IART) reported a net income of -$516.8M in fiscal year 2025, with a net profit margin of -31.6%.

What is Integra Lifesciences Hldgs Cp's EBITDA?

Integra Lifesciences Hldgs Cp (IART) had EBITDA of -$433.6M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Integra Lifesciences Hldgs Cp have?

As of fiscal year 2025, Integra Lifesciences Hldgs Cp (IART) had $235.0M in cash and equivalents against $726.6M in long-term debt.

What is Integra Lifesciences Hldgs Cp's gross margin?

Integra Lifesciences Hldgs Cp (IART) had a gross margin of 50.9% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Integra Lifesciences Hldgs Cp's operating margin?

Integra Lifesciences Hldgs Cp (IART) had an operating margin of -30.2% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Integra Lifesciences Hldgs Cp's net profit margin?

Integra Lifesciences Hldgs Cp (IART) had a net profit margin of -31.6% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Integra Lifesciences Hldgs Cp's return on equity (ROE)?

Integra Lifesciences Hldgs Cp (IART) has a return on equity of -49.5% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Integra Lifesciences Hldgs Cp's free cash flow?

Integra Lifesciences Hldgs Cp (IART) generated -$31.1M in free cash flow during fiscal year 2025. This represents a -224.4% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Integra Lifesciences Hldgs Cp's operating cash flow?

Integra Lifesciences Hldgs Cp (IART) generated $50.4M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

What are Integra Lifesciences Hldgs Cp's total assets?

Integra Lifesciences Hldgs Cp (IART) had $3.6B in total assets as of fiscal year 2025, including both current and long-term assets.

What are Integra Lifesciences Hldgs Cp's capital expenditures?

Integra Lifesciences Hldgs Cp (IART) invested $81.4M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Integra Lifesciences Hldgs Cp spend on research and development?

Integra Lifesciences Hldgs Cp (IART) invested $99.0M in research and development during fiscal year 2025.

Does Integra Lifesciences Hldgs Cp buy back shares?

Yes, Integra Lifesciences Hldgs Cp (IART) spent $221K on share buybacks during fiscal year 2025, returning capital to shareholders by reducing shares outstanding.

What is Integra Lifesciences Hldgs Cp's current ratio?

Integra Lifesciences Hldgs Cp (IART) had a current ratio of 2.54 as of fiscal year 2025, which is generally considered healthy.

What is Integra Lifesciences Hldgs Cp's debt-to-equity ratio?

Integra Lifesciences Hldgs Cp (IART) had a debt-to-equity ratio of 0.70 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Integra Lifesciences Hldgs Cp's return on assets (ROA)?

Integra Lifesciences Hldgs Cp (IART) had a return on assets of -14.3% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Integra Lifesciences Hldgs Cp's Altman Z-Score?

Integra Lifesciences Hldgs Cp (IART) has an Altman Z-Score of 0.74, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Integra Lifesciences Hldgs Cp's Piotroski F-Score?

Integra Lifesciences Hldgs Cp (IART) has a Piotroski F-Score of 4 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Integra Lifesciences Hldgs Cp's earnings high quality?

Integra Lifesciences Hldgs Cp (IART) has an earnings quality ratio of -0.10x, considered mixed quality. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Integra Lifesciences Hldgs Cp cover its interest payments?

Integra Lifesciences Hldgs Cp (IART) has an interest coverage ratio of -5.7x, meaning it can struggle to cover its interest obligations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Integra Lifesciences Hldgs Cp?

Integra Lifesciences Hldgs Cp (IART) scores 38 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is a 0-100 composite of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.